Connect with us

Health

Oxford Launches World’s First Human Trial of Vaccine Against Bundibugyo Ebola

Published

on

Scientists at the University of Oxford have launched the world’s first human clinical trial of a vaccine targeting the Bundibugyo strain of Ebola as health authorities work to contain a growing outbreak in the Democratic Republic of the Congo and Uganda.

The Phase I trial will evaluate the vaccine’s safety and its ability to trigger an immune response in 50 healthy adult volunteers aged between 18 and 55. Researchers have begun recruiting participants, with vaccinations expected to start in the coming weeks after regulatory approval for the study.

The trial comes as the Bundibugyo Ebola outbreak continues to expand across Central Africa. According to the Democratic Republic of the Congo’s Ministry of Health, 1,926 confirmed cases and 702 deaths had been recorded across five provinces as of July 11. Uganda reported 20 confirmed infections, including two deaths, on July 12. Health officials have identified 10 provinces in Congo, including the capital Kinshasa, as high-risk areas.

The University of Oxford’s Vaccine Group said the study represents the first effort to test a vaccine specifically designed to protect against the Bundibugyo strain in humans. While vaccines exist for other Ebola virus species, no approved vaccine currently targets Bundibugyo Ebolavirus.

Nicole Lurie, Executive Director of Preparedness and Response at the Coalition for Epidemic Preparedness Innovations (CEPI), described the trial as an important step in the international response to the outbreak.

“Every step that brings a safe and effective vaccine closer helps strengthen our ability to protect vulnerable communities, save lives and bring this outbreak under control,” Lurie said, adding that Oxford’s work marks a significant milestone in efforts to combat the disease.

See also  Portugal’s Medical Helicopters Cut Emergency Response Times Across Remote Areas

Researchers are also preparing additional clinical studies in Uganda, subject to approval from local regulators. Those trials are expected to be carried out through a partnership involving the Medical Research Council/Uganda Virus Research Institute and the London School of Hygiene and Tropical Medicine’s Uganda Research Unit.

Jean Kaseya, Director General of the Africa Centres for Disease Control and Prevention, welcomed the progress while stressing the importance of maintaining rigorous scientific and regulatory standards.

He said that although early-stage clinical trials will not provide an immediate solution for communities currently affected by the outbreak, they remain essential for developing medical tools capable of responding to both the current emergency and future Ebola outbreaks.

The Bundibugyo strain is one of several Ebola virus species known to infect humans and has caused multiple outbreaks in Africa over the past two decades. Public health officials continue to focus on surveillance, patient care, contact tracing and infection control measures while researchers work to develop vaccines and treatments that can help reduce the impact of the disease.

The Oxford trial is expected to provide initial data on the vaccine’s safety and immune response, laying the foundation for larger studies if the early results prove successful.

Health

Good Sleep May Matter More Than Diet or Exercise for Teenagers’ School Performance

Published

on

Good sleep may have a stronger influence on teenagers’ academic performance and social lives than diet, exercise or screen time, according to new research examining the daily factors that shape young people’s well-being.

The findings suggest that sleep could be particularly important for children experiencing symptoms of depression, anxiety or psychotic-like experiences, which have been linked to difficulties at school and in relationships.

Researchers examined data from more than 6,000 children for academic performance and more than 7,000 for social difficulties. The participants were aged between 10 and 13 and were assessed on four lifestyle factors: sleep quality, screen use, physical activity and diet.

Children showing symptoms of mental health difficulties generally performed worse academically and experienced more social problems. However, researchers found that lifestyle habits appeared to explain a significant part of this relationship, with sleep standing out as the most important factor.

“We expected sleep to be important, but we didn’t expect it to stand out so clearly above other lifestyle factors, particularly screen time,” said Jason Smucny, the study’s lead author at the University of California, Davis.

Researchers said poor sleep can cause daytime tiredness, problems with concentration and weaker executive functioning, all of which can make it harder for students to learn, complete schoolwork and perform well in examinations.

Sleep may also affect relationships. Disrupted or inadequate sleep can contribute to irritability and social withdrawal, potentially making it harder for young people to communicate with friends and maintain healthy relationships.

The researchers said their findings point to sleep quality as an important pathway through which early mental health symptoms can affect everyday functioning.

See also  Europe Faces Rising Threat of Tropical Diseases as Mosquito Season Intensifies

Tara Niendam, the study’s senior author, said parents, teachers and health professionals often concentrate on symptoms such as anxiety and depression, but families are also concerned about how those difficulties affect school performance, friendships and daily activities.

The research suggests that improving sleep routines could be one practical way of supporting young people facing these challenges.

Adolescents have increasingly struggled to get enough sleep, with previous research indicating that teenage sleep levels have declined over recent decades. School demands, social activities, technology use and changing schedules can all interfere with regular sleeping patterns.

The researchers stressed that better sleep cannot address every mental health problem. However, establishing consistent sleep routines may support emotional health and help young people manage the demands of school and social life.

With summer giving students an opportunity to recover from demanding school schedules, the findings highlight the potential importance of using the break to establish healthier and more consistent sleeping habits before the new academic year begins.

Continue Reading

Health

Study Suggests GLP-1 Weight-Loss Drugs May Lower Fracture Risk in People With Type 2 Diabetes

Published

on

A large US study has found that GLP-1 medicines, including widely prescribed treatments such as Ozempic, may reduce the risk of serious bone fractures in people with type 2 diabetes, challenging concerns that rapid weight loss associated with the drugs could weaken bones.

Researchers reported that patients treated with GLP-1 medicines had a 21% lower risk of fragility fractures over a three-year period compared with similar patients who received DPP-4 medicines, another class of drugs commonly used to manage type 2 diabetes.

The findings are based on an analysis of health records from more than 133,000 adults aged between 50 and 90 in the United States who were treated for type 2 diabetes between 2015 and 2022.

People living with type 2 diabetes face a greater risk of fractures caused by low-energy incidents, such as falls from standing height, even though they often have normal or higher-than-average bone density. Researchers said this may be linked to reduced bone strength, changes in bone structure and faster bone loss rather than bone density alone.

The study found the greatest reductions in vertebral fractures, which declined by 32%, while hip and femur fractures fell by 30% among patients taking GLP-1 medicines.

Researchers also noted that the lower fracture risk appeared to be independent of changes in body weight or blood sugar control. This raises the possibility that the medicines may have a direct effect on bone health rather than reducing fractures simply through weight loss or improved diabetes management.

The results challenge long-standing concerns that rapid weight loss could increase fracture risk by reducing bone density. Those concerns have accompanied the growing use of GLP-1 medicines, which have become increasingly popular for treating both type 2 diabetes and obesity.

See also  WHO Warns Childhood Obesity in Europe Remains at “Life-Threatening” Levels

Despite the encouraging findings, the researchers stressed that the study does not establish a direct cause-and-effect relationship. Because the research was based on observational health records rather than a randomized clinical trial, other factors may have influenced the results. Differences in physical activity, muscle strength, nutrition and existing bone health could all have contributed to the lower fracture rates.

The study also found no evidence that GLP-1 medicines reduced fracture risk among people who were taking the drugs without having type 2 diabetes. That suggests the apparent benefit may be specific to patients with diabetes and may not extend to those using the medicines solely for weight management.

The authors said additional prospective clinical trials are needed to confirm whether GLP-1 medicines provide direct protection against fractures and to determine whether any benefits continue during longer periods of treatment.

The findings add to growing research into the wider health effects of GLP-1 medicines as their use continues to expand around the world for diabetes care and weight management.

Continue Reading

Health

Greece Reports Rising West Nile Virus Cases as Europe Faces Active Summer Outbreak

Published

on

Greece is experiencing a sharp rise in West Nile virus infections, with health authorities warning that the mosquito-borne disease is spreading more widely than confirmed case numbers suggest. The country, alongside Italy, has recorded the highest level of virus activity in Europe this season.

Greece’s National Public Health Organisation reported 23 new infections during the past week. Since the start of the transmission season in spring through August 5, the country has confirmed 65 cases. Of those, 54 patients developed severe neurological complications, including encephalitis, meningitis or acute flaccid paralysis, while 11 experienced mild symptoms or no significant effects on the central nervous system.

The outbreak has resulted in six deaths, all involving patients over the age of 65 who suffered severe neurological illness.

Health officials cautioned that the confirmed figures represent only a fraction of the virus’s actual spread. Based on seroepidemiological data, authorities estimate that for every patient diagnosed with serious neurological disease, about 140 other people may have been infected without being diagnosed because they developed mild symptoms or none at all.

The virus continues to circulate across several regions of Greece. Cases have been identified in 25 municipalities covering Attica, Thessaly and Central Macedonia. The highest concentration has been recorded in Attica, where public health officials say transmission has been particularly intense this summer.

Of the 65 confirmed patients, 20 remain in hospital. Twelve are receiving treatment in general wards, while eight are in intensive care units. Thirty-eight patients have been discharged, and one person did not require hospital treatment.

See also  Diabetes Cases in the UK Reach Record High, Affecting One in Five Adults

The outbreak is part of a broader rise in West Nile virus activity across Europe. According to the European Centre for Disease Prevention and Control (ECDC), human infections have also been confirmed in Italy, Romania, France, North Macedonia, Spain and Germany through July 29.

The ECDC has identified 49 affected areas across seven European countries. Italy accounts for the largest number, with 30 affected areas, followed by Greece with eight. Romania has four affected areas, while France, North Macedonia and Spain each have two, and Germany has one.

Italy has also reported the highest number of confirmed human infections in Europe this season, with 94 cases. North Macedonia and Spain have each recorded seven cases, Romania has reported five, France two and Germany one.

West Nile virus is transmitted primarily through the bites of infected mosquitoes. Most infected people experience either mild flu-like symptoms or no symptoms at all. In a small proportion of cases, particularly among older adults and people with underlying health conditions, the infection can lead to serious neurological disease.

Public health authorities are urging residents and visitors to reduce mosquito exposure by using insect repellent, wearing protective clothing and eliminating standing water where mosquitoes breed as surveillance and prevention efforts continue throughout the summer.

Continue Reading

Trending